Introduction {#s1}
============

*Moraxella catarrhalis* is a gram-negative aerobic diplococcus and an exclusive human respiratory pathogen that for a long time used to be considered a purely human commensal [@pone.0064422-Catlin1]. However, *M. catarrhalis* is the third most frequent bacterial pathogen causing otitis media disease in children (after *Streptococcus pneumoniae* and non-typeable *Haemophilus influenzae* (NTHI)), and is a major cause of exacerbations in adults with chronic obstructive pulmonary disease (COPD) [@pone.0064422-Enright1]. Further, between 50--85% of all children experience at least one acute otitis media (AOM) episode before 3 years of age [@pone.0064422-Murphy1], [@pone.0064422-Rovers1], and the disease is associated with high costs. In addition, chronic and frequent recurrent AOM can lead to delayed speech development and language learning, due to hearing impairment. Moreover, complications including mastoiditis, and in rare cases even meningitis, may develop as a result of such middle ear infections [@pone.0064422-Cripps1], [@pone.0064422-Murphy2].

Since otitis media (OM) is a polymicrobial disease, an effective vaccine will have to protect against the 3 main bacterial causative agents of OM, including *M. catarrhalis,* and several vaccine related studies have already been performed to identify potential single vaccine candidates. These include various outer membrane proteins (OMPs) and lipooligosaccharide [@pone.0064422-Mawas1], [@pone.0064422-Murphy3]. Others have used a genome-wide data mining approach to identify novel antigens [@pone.0064422-Ruckdeschel1]. Of the putative antigens so far identified, the ubiquitous surface proteins A (UspA1, UspA2, and UspA2H) [@pone.0064422-Chen1], [@pone.0064422-Chen2], involved in adherence [@pone.0064422-Lafontaine1] and serum resistance [@pone.0064422-Attia1], have been shown to provide some protection in animal models using active vaccination or passive immunization strategies. Other potential candidates include the IgD-binding protein Hag/MID, a human epithelial cell adhesin and B cell mitogen, [@pone.0064422-Forsgren1], and it has been reported that a monoclonal antibody specific for the outer membrane protein CopB, an iron-regulated protein involved in iron uptake from transferrin and lactoferrin, enhanced pulmonary clearance of *M. catarrhalis* in a mouse model [@pone.0064422-Aebi1]. Finally, the porin OmpCD, an adhesin, was reported to enhance pulmonary clearance upon immunization [@pone.0064422-Murphy4], and at the time that this research project began, appeared to be the most appropriate potential vaccine candidate to act as a positive control in *in vivo* immunization experiments.

The ANTIGENome technology offers another approach in the search for vaccine candidates and has been successfully applied to identify novel protective antigens from several other bacterial pathogens [@pone.0064422-Fritzer1], [@pone.0064422-Meinke1], [@pone.0064422-Meinke2]. The technology generates many thousands of potential peptide antigen candidates that are then screened using magnetic-activated cell sorting (MACS) methods against well characterized human sera to identify novel protein vaccine candidates.

We have applied this technology and selected 214 protein candidates, among them the previously described protective proteins, UspA, Hag, CopB and OmpCD. Further validation by *in vitro* assays and finally in a murine model of *Moraxella* pulmonary clearance identified three proteins from *M. catarrhalis* as novel protective vaccine candidates. The functional characterization of one of these candidates, the surface protein Msp22, in *Moraxella* showed that it possesses heme-dependent peroxidase activity.

Materials and Methods {#s2}
=====================

Ethical statement {#s2a}
-----------------

All human serum samples used for these studies were collected according to the general national ethical guidelines and upon consent from individual subjects. Sera from healthy individuals were collected for this and similar studies by Intercell with written consent given by each individual specifically for this study. Collection of sera at the Erasmus University Medical Center (Rotterdam) was approved specifically for this study by the medical ethical Committee of the Erasmus MC (MEC-2-12-176) with patient consent given (or informed consent by parents or guardians in case of children). Human sera were also collected at the Semmelweis University as approved specifically for this study by the ethical committee of Semmelweis University. All animal experiments were approved by Stockholm\'s Norra djurförsöksetiska nämnd and were conducted in agreement with the European Communities Council Directive 86/609/EEC and the Swedish animal protection legislation. Mice were scored and sacrificed according to the obtained ethical permission.

Bacterial strains and growth conditions {#s2b}
---------------------------------------

*M. catarrhalis* strain RH4 was originally isolated from the blood of an infected patient [@pone.0064422-Christensen1] and strain BBH18 was from the sputum of a COPD patient during an exacerbation [@pone.0064422-Mollenkvist1]. Both strains were obtained from Arne Forsgren and Kristian Riesbeck (Malmö University Hospital, Sweden). Bacteria were grown in brain heart infusion (BHI) broth at 37°C with shaking (180 rpm) or on Columbia agar supplemented with 5% sheep blood (Biomérieux, Austria) or horse blood at 37°C.

Additional *M. catarrhalis* strains and clinical isolates (strains from various clinical samples (ear, sinus, nasal cavity and middle ear punctuate samples) were obtained from the Pediatric department at Semmelweis University (Budapest, Hungary), Erasmus University Medical Center (Rotterdam, The Netherlands) or were commercially acquired from GR Micro (London, UK). The following strains (Origin and IDs listed) from GR Micro isolated from patients with acute otitis media were used for the gene conservation studies: Australia (1090122, 1090127, 1091216), Belgium (1510233), Brazil (1041218, 3041116, 3041117), Canada (1022133, 1023257, 2022135), France (1502130, 3502122, 3502129), Germany (3517132, 3518116, 3519121, 3522120), Hungary (3650122, 3650134), Italy (1530120, 2530126, 3530121), Japan (2084130, 2085119, 3079119), Portugal (2560117), South Africa (3681122), South Korea (1070122, 1071124, 2070120), Spain (2554135, 3552130, 3553117), Sweden (3590123, 3590127, 3590135), Taiwan (3696117, 3696119, 3696126), Turkey (2660116, 2660119, 2660122), United States (1001118, 1001207, 1009124, 1009125).

*E. coli* cells were grown in LB broth at 37°C with shaking or on LB plates containing appropriate antibiotics (kanamycin and/or ampicillin).

For human sera adsorption, *E. coli* (DH5α transformed with pHIE11/pMAL9.1 [@pone.0064422-Etz1]) cells were grown to exponential phase and induced with 0.1 mM IPTG. The bacteria were harvested after one hour and washed three times with ice cold 2x PBS. Prior to addition to serum samples, the pellet was re-suspended in PBS (100 μL per 100 mL culture).

Selection of human sera for library screening {#s2c}
---------------------------------------------

A comprehensive collection of serum samples was obtained from the Department of Pediatrics, Semmelweis University (Budapest), the Erasmus University Medical Center (Rotterdam), and from Intercell AG (Vienna, Austria). In addition to the sera from otitis media patients, sera from healthy individuals or from patients in other disease groups (asthmatic patients, allergy) were also included in the studies, serving as relevant controls. All sera were aliquoted and stored at −80°C prior to use.

For the preparation of serum pools, all human sera were analyzed by ELISA and Western blot with *M. catarrhalis* cell lysates. The sera containing high titer of antibodies and showing a diversity of bands in the Western blot were selected to create serum pools of 5 individual sera per pool.

ELISA on bacterial cell lysates and recombinant proteins {#s2d}
--------------------------------------------------------

*M. catarrhalis* cells were grown in liquid medium at 37°C, 5% CO~2~ until a late log phase was reached. Cells were harvested by centrifugation (1,000 g, 10 min, 4°C) and washed twice with PBS. Bacteria were re-suspended in PBS containing protease inhibitors and then lysed on ice by sonication (2 min, pulse 5, 100% power) and the supernatant was collected by centrifugation. ELISA plates (96F Cert, Maxisorb Nunc-Immuno plate, 439454, Denmark) were coated with either bacterial lysates or recombinant proteins and human serum samples were tested at 3-fold dilutions from 1∶50 to 1∶36,450. Highly specific Horse Radish Peroxidase (HRP)-conjugated goat anti-human IgG (Southern Biotech, 2040-05, USA) was used for signal detection.

Peptide ELISA {#s2e}
-------------

N-terminally biotin-labeled peptides were coated onto streptavidin ELISA plates (Nunc, Denmark) at 5 µg/mL (in a 100 µL volume) and incubated overnight at 4°C. Sera were tested in duplicate at a 1∶1000 dilution. Horse Radish Peroxidase (HRP)-conjugated anti-human IgG antibodies (Southern Biotech) were used according to the manufacturer\'s recommendation (1∶1000 dilution). ABTS was used as a substrate for HRP and the absorbance read at 405 nm.

Preparation of IgGs from human serum pools {#s2f}
------------------------------------------

Prior to library screening, human serum pools were adsorbed against *E. coli* (DH5α transformed with pHIE11/pMAL9.1\]) cells in order to reduce background. The cell suspension was added to the serum pools (150 µL cell suspension per 800 µL serum) and rotated overnight at 4°C. The next day, the mixture was centrifuged and the supernatants were transferred into a clean tube. The whole procedure was carried out three times for each single serum pool.

The *E. coli* adsorbed human sera were heat-inactivated at 56°C for 45 min and centrifuged to remove precipitated proteins. The supernatant was filtered using a 0.22 μm syringe filter (Costar, USA) and IgGs were purified and biotinylated with the reagents provided by Pierce Biotechnology (USA), as previously described [@pone.0064422-Fritzer1], and subsequently used for library screening.

Construction of bacterial surface display libraries {#s2g}
---------------------------------------------------

Bacterial surface display libraries were generated as previously described [@pone.0064422-Fritzer1], [@pone.0064422-Etz1]. Briefly, genomic DNA from *M. catarrhalis* BBH18 was fragmented by DNase I digest (LamB library, DNase Shotgun Cleavage Kit (Novagen, USA)) or sonication (FhuA library, Sonopuls Ultrasonic Homogenizer HD2200 (Bandelin, Germany)). Blunt-ended DNA fragments of 50--200 bp or 150--600 bp were ligated with the *Sma*I digested frame-selection vector pMAL4.31. pMAL4.31 containing 50--150 bp or 150--600 bp DNA fragments from *M. catarrhalis* was transformed into DH10B electrocompetent *E. coli* cells (Invitrogen, USA). Plasmid DNA was isolated from the pool of transformed clones, and the DNA inserts cloned into the platform vectors pMAL9.1 (FhuA, 150--600 bp) and pHIE14 (LamB, 50--150 bp) for surface display.

MACS screening {#s2h}
--------------

MACS (magnetic-activated cell sorting) screening using bacterial surface display libraries was performed as described previously [@pone.0064422-Fritzer1], [@pone.0064422-Etz1].

Cloning, expression and purification of recombinant *M. catarrhalis* proteins in *E. coli* {#s2i}
------------------------------------------------------------------------------------------

For recombinant expression of *M. catarrhalis* antigens, the PCR amplified gene or gene fragments to be expressed were cloned into pET28b+, a vector containing a kanamycin resistance cassette as well as a T7-RNA polymerase promoter. All proteins were expressed with N- or C-terminal His-tags without possible signal peptides. Protein expression was analyzed in small scale (2 mL) cultures, and protein solubility was determined based on centrifugation of lysed bacterial cultures and analysis of soluble (supernatant) and insoluble (pellet) fractions. Western blot with anti-His-tag antibodies was performed to confirm the expression of the recombinant protein. Proteins were purified from 2 L *E. coli* BL21(DE3) cultures carrying the pET28b+ vector encoding the antigens. Soluble proteins were purified using an IMAC column according to standard methods, insoluble proteins were purified by washing the inclusion bodies, solubilizing them in a buffer containing 6 M Guanidine hydrochloride (GuHCl), and subsequently applying them to an IMAC column. Bound proteins were eluted with 250 mM imidazole in denaturing buffer. Proteins were refolded by dilution with a buffer without GuHCl but containing L-Arginine (0.5 M) as an inhibitor of protein aggregation. After renaturation, proteins were dialyzed against 50 mM Tris-HCl, 150 mM NaCl buffer at pH 8.0 and decreasing concentration of L-Arginine (100 mM final). Alternatively, inclusion bodies were solubilized with 8 M urea and purified under denaturing conditions in the presence of 0.2% N-lauroylsarcosine. Proteins were then dialyzed against PBS, 0.2% N-lauroylsarcosine.

Preparation of whole cell membranes from *M. catarrhalis* {#s2j}
---------------------------------------------------------

Cells from a 1.5 L culture were harvested (4,500 rpm, 4°C, 60 min) and washed with PBS. The pellet was re-suspended in 100 mM Na~2~CO~3~ and sonicated on ice for 2 min (50%). After centrifugation (12,000 rpm, 4°C, 10 min) to remove cell debris, the supernatant was ultracentrifuged (40,000 rpm, 4°C, 90 min) and the pellet was washed with PBS (40,000 rpm, 4°C, 90 min). Finally, the pellet was re-suspended in 500 µL PBS.

Preparation of outer membrane vesicles from *M. catarrhalis* {#s2k}
------------------------------------------------------------

Cells from a 1.5 L culture (without or with 2 µM Desferal) were harvested (4,500 rpm, 4°C, 60 min) and washed with PBS. The cells were re-suspended in 50 mL EDTA buffer (0.05 M Na~2~HPO~4~, 0.15 M NaCl, 0.01 M EDTA, pH 7.4) and incubated at 56°C for 30 min at 75 rpm agitation with glass beads (1.7--2 mm). The culture was centrifuged (3,500 rpm, room temperature, 15 min) twice, and the supernatant containing the membrane vesicles was ultracentrifuged (40,000 rpm, 4°C, 90 min). The pellet was washed with PBS (40,000 rpm, 4°C, 60 min) and re-suspended in 500 µL PBS.

Generation of mouse immune serum against *M. catarrhalis* recombinant protein Msp22 {#s2l}
-----------------------------------------------------------------------------------

Msp22 with a His-tag at the C-terminus and expressed without lipidation in *E. coli* was purified using IMAC columns and utilized for the generation of Msp22-specific immune serum in mice. Female NMRI mice 6--8 weeks of age were bled by tail vein puncture to generate pre-immune sera, and were immunized three times intraperitoneally with 50 µg recombinant antigen per immunization, using Complete Freunds Adjuvant (CFA) or Incomplete Freunds Adjuvant (IFA) as adjuvant. Terminal bleeds were collected via the orbital sinus. Sera were heat-inactivated at 56°C for 30 minutes.

Immunization and challenge of mice {#s2m}
----------------------------------

Five to seven-week-old female C57/BL6 mice were kept under specific pathogen-free conditions in a standardized 12 hours light/dark cycle and received commercial food and water *ad libitum*. Before immunization on Day 0, 10 µL of blood was withdrawn from each mouse to prepare pre-immune serum samples. On days 0, 21 and 42, intranasal immunization of groups of 10 mice as controls with PBS or Intercell\'s proprietary adjuvant IC31^®^ [@pone.0064422-Schellack1] and with the respective adjuvanted proteins was performed as follows: 17.5 µL protein solution was mixed with 2.5 µL IC31^®^ (2000 nmol/mL KLK: 80 nmol/mL ODN1a), incubated for 30 minutes at room temperature and used to immunize mice within one hour of preparation. Adjuvant control mice received 17.5 µL 50 mM Tris/HCl pH 8.0 mixed with 2.5 µL IC31^®^. Immune sera were obtained on Day 63 (3 weeks after the last boost) and frozen at −20°C for storage.

Twenty-one days after the last boost, mice were infected intranasally with 40 µL (20 µL per nostril) live *M. catarrhalis* strain RH4, equaling approximately 5×10^6^ CFU. For mouse inoculation, *M. catarrhalis* RH4 was grown in BHI broth to an OD~620~ of 0.4. Bacteria were pelleted and re-suspended in PBS. Mice were held in a head-up vertical position during the inoculation and kept in that position for at least 10 seconds after the inoculation.

Euthanasia, tissue collection and bacterial culture {#s2n}
---------------------------------------------------

Mice were euthanized at 6 hours post-infection. Both lungs were removed, placed in 1 mL PBS plus protease inhibitor (Roche, Germany), homogenized using cell strainers (100 µm, Becton Dickinson and Company, USA) and used for serial plating to quantify viable bacteria.

For the evaluation of bacterial clearance due to immunization with recombinant proteins, several independent experiments were performed and the CFU in the lungs of the mice were normalized to an infectious dose of approximately 5×10^6^ CFU bacteria (actual dose varied between 3.8× to 5.9×10^6^ CFU) and analyzed with non-parametric Kruskal-Wallis tests and Dunńs post-testing.

Preparation of *M. catarrhalis* lysates {#s2o}
---------------------------------------

*M. catarrhalis* RH4 or BBH18 lysates were prepared from cultures grown in BHI broth. The cells were harvested, washed and re-suspended in PBS, then sonicated on ice using 2×30 second bursts. The protein concentration was measured using BCA protein assay reagent (Pierce Biotechnology).

Generation of the *msp22* gene deletion mutant {#s2p}
----------------------------------------------

The *M. catarrhalis* gene deletion mutant *msp22*Δ was generated by amplifying a ∼500 bp region up- and downstream of the msp22 gene from genomic DNA using the following oligonucleotide primers: 8666--5′-TGATATTCGCTGAGATGTGA-3′; 8667--5′-CCACTAGTTCTAGAGCGGCAGTGTGGTTCTTGCCATAAG-3′; 8668--5′-GCGTCAATTCGAGGGGTATCTAAAACATGCAGCAGCTAAG-3′; 8669--5′-GATGGCATCATACCAATCTT-3′. The flanking regions of the gene were ligated by overlap-extension PCR with a spectinomycin resistance cassette that was derived from the vector pR412T7 [@pone.0064422-Bijlsma1]. *M. catarrhalis* cells were rendered competent by washing with PBS containing 0.15% bovine gelatin. Transformation was achieved by adding the DNA fragments to the competent cell cultures, and subsequent plating on spectinomycin-containing blood agar plates (100 µg/mL). The numbers of CFUs were counted after overnight incubation at 37°C. *Msp22* gene-specific PCRs, sequencing and Southern blot analysis were performed to confirm the presence of the gene deletion.

Msp22 cloning for complementation, expression and purification in *M. catarrhalis* BBH18 using complementation plasmid pEMCJH04-KAN {#s2q}
-----------------------------------------------------------------------------------------------------------------------------------

The complete *msp22* gene and a region of approximately 200 bp upstream of the gene was amplified using genomic DNA as template and primers 8825 and 8826, and cloned into pEMCJH04-KAN [@pone.0064422-Hays1] resulting in pEMCJH04-KAN-Msp22. Mini prep DNA of pEMCJH04-KAN-Msp22 and primers 8825 and 8860 (primer containing 6xHis-tag) were used for PCR amplification (see listing below). The resulting fragment was *Bam*HI/*Pst*I digested and ligated with *Bam*HI/*Pst*I digested pEMCJH04-KAN (→pEMCJH04-KAN-Msp22-HIS). Transformation of the ligation into competent *M. catarrhalis* wild type and gene deletion mutant *msp22*Δ cells was performed as described above. Transformed cells were plated on blood agar containing 50 µg/mL kanamycin. Clones were analyzed by colony PCR using the following primers: 8825--5′-ATATATGGATCCCATAACATAAATTGCCGTTGTCTTGG-3′; 8826--5′-ATATATCTGCAGCTATTTTTTCTTATAAGCCTTATGGC-3′; 8835--5′-ACTTTTGCTGAGTTGAAGGA-3′, 8836--5′-ACAAAATGTTGTAGCGGTCT-3′; 8860--5′-AAAACTGCAGCTAGTGGTGGTGGTGGTGGTGTTTTTTCTTATAAGC-3′.

Purification of Msp22 from *M. catarrhalis* {#s2r}
-------------------------------------------

*M. catarrhalis* wild type (negative control) and *M. catarrhalis* cells containing pEMCJH04-KAN-Msp22-HIS were plated on blood agar plates containing 0 or 50 µg/mL kanamycin. Fifteen mL of BHI medium was inoculated with several colonies from the plate and bacteria were grown for 5 hrs (37°C, 180 rpm). The culture was transferred to 150 ml BHI medium and grown overnight. The following day, the cultures were diluted in 1.5 L BHI medium and grown at 37°C, 180 rpm for 5 hrs (wt, negative control) or overnight (*M. catarrhalis* containing pEMCJH04-KAN-Msp22-HIS). The cells were harvested by centrifugation and frozen at −20°C until use.

The pellet was thawed and re-suspended in lysis buffer (50 mM Tris/HCl pH 8.0, 500 mM NaCl, 0.1% Triton X-100) containing protease inhibitors. Sonication on ice was performed 7×2 min (5×10% cycle, 100% power), and soluble and insoluble fractions were separated by centrifugation. Small scale Western blot analysis of crude lysate, soluble and insoluble fractions was performed to determine the solubility of the protein. The protein in the soluble fraction was purified using an IMAC affinity column. The protein bound to the column was washed with Tris/NaCl buffer (50 mM Tris/HCl pH 8.0, 500 mM NaCl, 0.5 mM DTT) containing 0.1% Triton X-100 (wash 0), buffer only (wash 1), 20 mM imidazole (wash 2) and 40 mM imidazole (wash 3) and then eluted in 50 mM Tris/HCl pH 8.0, 150 mM NaCl, 250 mM imidazole.

Luminol based heme staining {#s2s}
---------------------------

For heme staining, the protocol by Feissner *et al.* [@pone.0064422-Feissner1] was used. Briefly, SDS-PAGE was performed using non-reducing loading buffer and samples were not heat treated prior to loading. Proteins were subsequently blotted onto a nitrocellulose membrane, washed with PBS and incubated with the substrate luminol (SuperSignal West Femto Maximum Sensitivity Substrate Trial Kit, Pierce Biotechnology). Luminol/Enhancer solution and Stable Peroxidase Buffer were mixed at a 1∶1 ratio and added to the membrane, followed by exposure of the membrane to light-sensitive film, allowing the detection of proteins with heme-dependent peroxidase activity.

Results {#s3}
=======

Human sera for antigen identification recognize *M. catarrhalis* proteins {#s3a}
-------------------------------------------------------------------------

Antigen identification using human sera relies on the assumption that candidate antigens have induced seroconversion or an immune response in patients recovering from infection or in healthy individuals upon encounter with the pathogen without developing disease. For identification of *M. catarrhalis* vaccine candidate antigens, 414 sera from patients (children 1--10 years of age) with otitis media were collected over a three year period. This serum collection included 147 serum pairs taken from the same individual during acute and convalescent disease phase (294 samples) and 120 single serum samples taken either from the acute or convalescent phase from different patients. Human sera were further collected from children suffering from respiratory allergies or asthma (2--18 years) and healthy adults (18--40 years) having no recent history of middle ear disease or *M. catarrhalis* infection. The sera containing high titer of antibodies as measured by ELISA and showing a diversity of bands in the Western blot using whole *Moraxella* cell lysate were selected to create four different serum pools for antigen selection by bacterial surface display ([Table 1](#pone-0064422-t001){ref-type="table"}). In general, good antibody levels against *Moraxella* lysates were detected in the majority of sera, but we could not observe significant differences in IgG levels between samples obtained from patients in acute and convalescent phase. The sera for pooling were therefore selected mainly based on ELISA titer and Western blotting. Sera from both, healthy individuals and patients, had higher ELISA titers than the sera from patients with recurrent AOM, while the latter showed a more homogeneous banding pattern in Western blot as compared to the individual sera included in the other pools. Serum pool PMc36 contained sera from young patients (2--18 years) with respiratory allergies, PMc37 serum pool was derived from children with asthma (5--17 years), PMc39 serum pool included sera from the patients with recurrent otitis media and the serum source for IC20 serum pool were healthy individuals.

10.1371/journal.pone.0064422.t001

###### Human sera selected for antigen identification by peptide library screening.

![](pone.0064422.t001){#pone-0064422-t001-1}

  Serum pool                  Individual sera                                        Source                                   Purpose
  ------------ --------------------------------------------- ------------------------------------------------------- --------------------------
  **P39**       P4060.2, P4070.2, P4072.2, P4101.2, P4115.2        Patients with otitis media; age: 1-10 years           Antigen selection
  **IC20**           IC58B, IC84B, IC85B, IC86B, IC89B               Healthy individuals; age: 18--40 years              Antigen selection
  **P36**            P3792, P3801, P3819, P3832, P3861        Patients with respiratory allergies; age: 2--18 years   Control; other condition
  **P37**            P3918, P3923, P3941, P3943, P3965               Patients with asthma; age: 5--17 years           Control; other condition

Pool P39 consisted of individual sera collected from OM patients during the convalescent disease phase. Pool IC20 contained sera from healthy individuals. The additional 2 pools were used as controls for otitis media-unrelated antigen reactivity: Pool P37 (patients with asthma, age: 5--17 years). Pool P36 (patients with respiratory allergies, 8 months-- 18 years of age).

Selection of 23 *M. catarrhalis* vaccine candidate antigens by the ANTIGENome technology {#s3b}
----------------------------------------------------------------------------------------

In order to apply the ANTIGENome technology for the identification of novel *M. catarrhalis* vaccine candidates, genomic libraries were generated consisting of *E. coli* cells displaying random peptides of *M. catarrhalis* via the FhuA and LamB platforms on the bacterial cell surface. Approximately 600 clones of each library were sequenced in order to determine the quality of the libraries and to calculate the average insert sizes. Average insert sizes of 39 bp (LamB/1), 87 bp (LamB/2) and 199 bp (FhuA) covering the entire *M. catarrhalis* BBH18 genome 33 times (LamB/1), 56 times (LamB/2) and 38 times (FhuA), were represented by a total number of 1.6×10^6^ (LamB/1), 1.2×10^6^ (LamB/2) and 3.6×10^5^ (FhuA) *E. coli* clones, respectively. The first LamB library contained DNA inserts of an average size of 39 bp, therefore a second LamB library was generated with a larger average insert size.

Screening of the three genomic libraries was performed using IgGs purified from the four serum pools, resulting in 13 individual bacterial surface display screens (3 LamB screen with the LamB/1 library, 4 LamB screens with the LamB/2 library, and 6 FhuA screens) to identify novel vaccine antigens. Approximately 800 clones per screen were sequenced and the results matched to annotated ORFs using BLAST searching (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). A problem that occurred in the initial screens was the frequent selection of the Hag/MID, UspA1/UspA2H antigens. Therefore, serum pools IC20 and PMc39 were additionally adsorbed against 3 UspA2H and 4 (IC20 IgG pool) or 6 (P39 IgG pool) Hag/MID library clones that covered the immunodominant regions of these proteins. The selection of 6 Hag/MID library clones for adsorption resulted in a strong reduction of Hag/MID clones in the screen using P39 serum pool, and a relative increase in the selection of the remaining antigens.

In total, 214 candidates were selected by the ANTIGENome approach and positively confirmed by Western blot analysis using the human IgG pools that were initially used for library screening. The most frequently selected antigens in all screens included the previously published antigens Hag/MID (493 hits [@pone.0064422-Forsgren2]), the UspA1 and UspA2H proteins (131 hits [@pone.0064422-Chen1]) as well as LbpB (39 hits [@pone.0064422-Bonnah1], [@pone.0064422-Yu1]) and CopB (35 hits [@pone.0064422-Aebi2], [@pone.0064422-Mathers1]). However, a number of less well characterized proteins, such as a TonB dependent receptor (MCR_0076, 13 hits), an outer membrane protein (MCR_1742, 24 hits), a carboxypeptidase (MCR_1010, 48 hits), and MhuA (MCR_0739, 15 hits) were frequently detected in addition to these well characterized antigens. Certain antigens were preferably selected when screening the FhuA library. These candidates included among others: Hag/MID (FhuA: 349 hits vs. LamB: 144 hits); UspA2H (FhuA: 81 hits vs. LamB: 4 hits); UspA1 (FhuA: 39 hits vs. LamB: 7 hits); and the aconitate hydratase (FhuA: 42 hits vs. LamB: 1 hit). In contrast, McmA was found 29 times in LamB screens, but was only selected once using the FhuA library. Many other antigens were identified equally frequent in both screens. These results confirm that the ANTIGENome technology is a very valuable and comprehensive approach for the identification of novel antigens as potential vaccine candidates. Moreover, the utilization of two different surface display libraries, expressing smaller (LamB) and larger (FhuA) peptides, may also -- besides mainly linear epitopes -- allow for the selection of conformational epitopes.

Following initial antigen identification, several *in vitro* and *in vivo* analyses were performed to further reduce the number of selected vaccine candidates. Initially, all 214 candidates were tested for their gene distribution among 47 *M. catarrhalis* isolates. Based on this PCR analysis, 196 antigens were present in at least 43 of 47 *Moraxella* strains, whereas only 18 candidates were present in less than 90% of all isolates tested.

In order to evaluate the immunogenicity of individual antigens in humans, an ELISA using synthetic peptides corresponding to the epitope bearing regions of the antigenic proteins identified by the genomic screens was performed using the individual sera from the four human serum pools. The peptides were designed based on bioinformatic analysis of the selected clones encoding immunogenic epitopes and synthesized with an N-terminal biotin-tag. In case of longer antigenic fragments (more than 26 amino acid residues), overlapping peptides were generated. The 402 peptides were selected from 110 antigens according to their frequency of being selected by the antigen screens as well as their annotation (e.g. predicted to be surface located, antigenic or secreted peptides/proteins). The 50 most reactive peptides are listed in [Tables 2](#pone-0064422-t002){ref-type="table"} and [3](#pone-0064422-t003){ref-type="table"}. Several of the most reactive peptides corresponded to antigens frequently found in the screens, such as PcnB/MCR_1836, GroES/MCR_1494, PrfC/MCR_1681, GidA/MCR_1350, RpoC/MCR_0258, AcnB/MCR_0394 and McmA/MCR_1652.

10.1371/journal.pone.0064422.t002

###### ELISA data for the 50 most reactive *M. catarrhalis* peptides -- Average ELISA titers for groups of sera.

![](pone.0064422.t002){#pone-0064422-t002-2}

  Peptide                                     Annotation                                 Average (OM)   Average (Asthma)   Average (Healthy)   Average (All)
  ------------- ----------------------------------------------------------------------- -------------- ------------------ ------------------- ---------------
  MCR_1292-02    phosphatidylethanolamine Kdo2-lipid A phosphoethanolamine transferase       553              486                 507               518
  MCR_0412-03                            hypothetical protein                                413              396                 412               407
  MCR_1728-03                            Ppx/GppA phosphatase                                445              410                 294               387
  MCR_1387-01                               ribonuclease PH                                  428              474                 219               377
  MCR_1836-07                             poly(A) polymerase                                 479              358                 260               373
  MCR_0169-04                         excinuclease ABC subunit A                             511              394                 154               363
  MCR_1494-02                          chaperonin protein Cpn10                              431              390                 239               359
  MCR_0081-02                            prolyl endopeptidase                                348              377                 317               347
  MCR_1728-05                            Ppx/GppA phosphatase                                347              351                 276               326
  MCR_1596-01                    phospholipid/glycerol acyltransferase                       333              265                 332               311
  MCR_1690-04                extracellular solute-binding protein family 3                   280              401                 241               306
  MCR_0036-01                          glutamate-cysteine ligase                             334              353                 211               302
  MCR_0604-04                    Fe-S protein assembly chaperone HscA                        316              291                 244               286
  MCR_1619-10                               ribonuclease E                                   303              347                 178               277
  MCR_1200-01                         2-isopropylmalate synthase                             370              244                 173               269
  MCR_0036-03                          glutamate-cysteine ligase                             233              240                 338               268
  MCR_1283-01                            glycine dehydrogenase                               340              287                 153               265
  MCR_0092-01                        3-ketoacyl-CoA thiolase FadA                            301              260                 211               260
  MCR_1683-02                              DNA polymerase I                                  304              298                 140               251
  MCR_1681-01                       peptide chain release factor 3                           280              231                 216               245
  MCR_1596-02                    phospholipid/glycerol acyltransferase                       230              271                 230               243
  MCR_1487-01                     ubiquinone biosynthesis hydroxylase                        268              283                 158               238
  MCR_0131-02                         nitric oxide reductase NorB                            250              251                 144               217
  MCR_1320-02                 cbb3-type cytochrome c oxidase subunit CcoP                    243              273                 111               211
  MCR_0321-03                       lysophospholipase-like protein                           217              201                 181               201
  MCR_0604-02                    Fe-S protein assembly chaperone HscA                        271              165                 152               201
  MCR_0131-04                         nitric oxide reductase NorB                            263              247                 69                197
  MCR_0996-04                            hypothetical protein                                248              225                 107               197
  MCR_0934-05                           polyphosphate kinase 2                               257              204                 108               194
  MCR_1003-02                             LysM domain protein                                169              300                 114               193
  MCR_1735-02                      M48 family zinc metallopeptidase                          213              231                 129               192
  MCR_1295-02                           leucyl-tRNA synthetase                               222              208                 119               186
  MCR_0439-03                        penicillin-binding protein 1A                           194              200                 154               184
  MCR_0078-01                            hypothetical protein                                193              211                 136               180
  MCR_0169-03                         excinuclease ABC subunit A                             240              226                 58                179
  MCR_1672-02                      pepSY-associated membrane protein                         149              229                 163               178
  MCR_0692-03                            hypothetical protein                                216              213                 96                177
  MCR_0092-02                        3-ketoacyl-CoA thiolase FadA                            276              153                 78                176
  MCR_0258-01                 DNA-directed RNA polymerase subunit beta\'                     170              156                 194               173
  MCR_0321-04                       lysophospholipase-like protein                           191              180                 132               169
  MCR_0791-02                    nicotinate-nucleotide diphosphorylase                       184              205                 113               168
  MCR_0625-01                        penicillin-binding protein 1B                           210              177                 106               167
  MCR_0394-04                                  aconitase                                     200               93                 201               167
  MCR_0136-02                       conserved hypothetical protein                           178              191                 129               166
  MCR_1690-01                extracellular solute-binding protein family 3                   153              207                 136               164
  MCR_1652-02                 peptidase M16 inactive domain protein McmA                     183              206                 92                162
  MCR_1350-06      tRNA uridine 5-carboxymethylaminomethyl modification enzyme GidA          221              178                 63                158
  MCR_0405-01                   tetratricopeptide repeat family protein                      145              202                 129               158
  MCR_1295-01                           leucyl-tRNA synthetase                               184              134                 129               151
  MCR_0405-03                   tetratricopeptide repeat family protein                      184              139                 123               151

The peptides are named by the ORF followed by a number indicating the individual peptide for the respective ORF. Individual sera were obtained from asthma patients and healthy individuals and convalescent sera patients with otitis media (OM). Listed are the 50 peptides with highest average ELISA units of the 402 peptides analyzed. ELISA units were calculated as 1,000×\[(A~405~ wells with serum) -- (A~405~ wells with secondary antibody alone)\]. The serum ELISA units were additionally corrected for the background reactivity of sera with streptavidin, by subtracting the values obtained with streptavidin coated wells in the absence of peptide from the values obtained in the wells containing bound peptides.

10.1371/journal.pone.0064422.t003

###### ELISA data for the 50 most reactive *M. catarrhalis* peptides -- ELISA titers for individual sera.
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                 OM    Asthma   Healthy individuals                                                                                 
  ------------- ----- -------- --------------------- ----- ----- ----- ----- ----- ------ ----- ----- ----- ----- ----- ----- ----- -----
  MCR_1292-02    677    388             370           789   566   526   706   696    8     626   396   629   504   155   403   846   518
  MCR_0412-03    602     68             226           778   411   390   420   416   423    505   216   339   518    0    446   755   407
  MCR_1728-03    612    352             197           753   393   365   391   428   424    381   427   253   311    0    356   552   387
  MCR_1387-01    506    397             172           672   448   373   404   383   1008   392   185   192   139    0    64    700   377
  MCR_1836-07    569    624             433           484   349   414   252   500   393    399   244   247   386    0    233   435   373
  MCR_0169-04    472    1008            159           574   408   444   336   635   355    531   111   152   134   64    64    357   363
  MCR_1494-02    462    408             196           705   407   409   376   428   658    321   169   189   232    0    136   640   359
  MCR_0081-02    522     83             199           623   398   261   464   471   456    478   18    277   420    0    271   617   347
  MCR_1728-05    520     58             180           668   364   294   428   426   391    399   109   195   416    0    208   560   326
  MCR_1596-01    236    306             117           619   311   408   258   366   257    253   191   318   217    0    721   402   311
  MCR_1690-04    139    248             120           663   210   299   300   350   417    692   247   102   524   65    57    455   306
  MCR_0036-01    353    215             117           631   334   354   372   346   506    305   237   201   204    0    122   530   302
  MCR_0604-04    334    398             303           354   178   331   442   459   292    260    0    203   121    0    562   335   286
  MCR_1619-10    396     0              83            671   330   336   450   357   458    209   259   198   94     0    80    516   277
  MCR_1200-01    398    784             103           502   237   194   341   273   297    230   78    141   104    0    165   455   269
  MCR_0036-03    277    106             275           114   147   477   429   92    253    150   277   214   386    0    715   375   268
  MCR_1283-01    346    338             115           602   355   286   397   353   312    258   115   97    88     0    131   450   265
  MCR_0092-01    187    822             76            273   182   264   132   475   102    379   212   253   201   93    253   255   260
  MCR_1683-02    458     9              121           517   454   264   257   266   604    281   83    102   269    0    48    283   251
  MCR_1681-01    284    725             109           205   153   205   167   388   124    291   183   161   706    0    95    119   245
  MCR_1596-02    180    271             98            363   153   313   199   208   214    394   338   727   140    0    96    188   243
  MCR_1487-01    158    132             84            567   318   351   412   470    0     243   288   86    115    0    78    512   238
  MCR_0131-02    173    468             141           300   211   207   211   327   181    208   327   168   129   115   103   204   217
  MCR_1320-02    158    112             60            538   308   284   288   354   255    194   274   46    86     0    55    367   211
  MCR_0321-03    214    126              0            471   238   255   257   222    26    210   292   247   89    27    157   383   201
  MCR_0604-02    186    346             161           370   261   301   191   162   155    224   94    122   123    0    245   272   201
  MCR_0131-04    31     945             79            77    85    361   93    580    25    272   265   78    73     0    86    106   197
  MCR_0996-04    352    260             11            521   154   192   277   284   350    173   39    55    54    80     0    345   197
  MCR_0934-05    232    376             48            449   182   256   254   301   258    193   15    42    68     0    29    400   194
  MCR_1003-02    124    233              0            432   40    182   727   216   199    242   118   73    76     0    143   280   193
  MCR_1735-02    122    202             35            474   215   229   238   298   207    167   244   74    88     0    84    399   192
  MCR_1295-02    223     65             35            593   228   189   282   295   210    254    0    69    67     0    58    400   186
  MCR_0439-03    95     312             103           299   180   173   144   159   242    173   284   374   132    0    70    196   184
  MCR_0078-01    177     0              132           462   177   207   319   284   252    198    0    73    97     0     0    508   180
  MCR_0169-03    176    576             59            359   74    193   404   259   100    322   45    30    10     0    17    233   179
  MCR_1672-02    247    290             78            168   100   10    240   101   410    112   282   123   99    143   60    390   178
  MCR_0692-03    348    229             56            341   163   158   205   266   256    148   189   95    70     0    48    265   177
  MCR_0092-02    325    313             226           97    427   265   103   67    201    89    307   117   73     0    69    131   176
  MCR_0258-01    157    143             34            468   102   114   193   240   132    216    0    52     0     0    666   253   173
  MCR_0321-04    199    119              0            341   191   296   252   192    19    202   235   168   66     0    94    332   169
  MCR_0791-02    285     61             80            308   216   152   218   214   153    233   206   39    159    0    78    287   168
  MCR_0625-01    202    139             53            476   204   187   226   272   200    188    0    35    46     0    46    405   167
  MCR_0394-04    297    513             76            44    202   65    78    51     98    81    159   490    2     0    305   208   167
  MCR_0136-02    83     154             58            368   200   202   237   278   170    166   103   150   65     0    70    359   166
  MCR_1690-01    162    136             91            306   112   108   205   165   350    152   164   172   157    0    56    294   164
  MCR_1652-02    109    119              4            474   159   234   297   278   241    158   57    57    11     0    13    380   162
  MCR_1350-06    245    317             143           307   165   147   193   242   145    126   185    1    10     0     0    306   158
  MCR_0405-01    128    202             45            237   150   106   179   229   239    116   249   43    42    292   35    232   158
  MCR_1295-01    158    167             71            224   216   265   164   122   109    169   104   131   117    0    70    329   151
  MCR_0405-03    534    106             46            232   154   29    214   129   118    101   132   168   154    0    70    225   151

For legend see [Table 2](#pone-0064422-t002){ref-type="table"}.

A final selection of 23 promising antigens for recombinant protein production and further *in vivo* evaluation was made based on the number of screen hits, data obtained from the serological studies, and the bioinformatic and gene distribution analyses (see [Table 4](#pone-0064422-t004){ref-type="table"}). All 23 candidates were present in at least 44 of the 47 tested *Moraxella* isolates and the majority of the antigens were predicted to be localized in the outer membrane. In addition, proteomic studies with *M. catarrhalis* membrane fractions were performed to support antigen selection (data not shown). As shown in [Table 4](#pone-0064422-t004){ref-type="table"}, four candidates (OppA, M16-like peptidase, MhuA and MsrAB) were found in all membrane preparations, whole membrane, outer membrane vesicles and outer membrane vesicles isolated from cultures grown in iron-depleted medium (as a variety of virulence factors are induced by low iron levels). Three candidates (hypothetical proteins MCR_0063, MCR_0691, MCR_0692) were found in the whole membrane and in outer membrane vesicles, and seven further candidates were detected in one of the three membrane preparations.

10.1371/journal.pone.0064422.t004

###### *M. catarrhalis* antigens selected by the ANTIGENome technology.
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  ID                                       Annotation                               aa     GD     Hits   1    2    3        4       5
  ------------ ------------------------------------------------------------------- ----- ------- ------ ---- ---- ---- ----------- ----
  MCR_0063                            hypothetical protein                          232   47/47    8     \+   \+        PP (9.84)   −
  MCR_0076\*                         TonB-dependent receptor                        913   44/47    13                   OM (9.52)   −
  MCR_0136                            hypothetical protein                          278   47/47    2                    PP (9.84)   \+
  MCR_0186                       outer membrane lipoprotein LolB                    190   46/47    6     \+               ? (2)     −
  MCR_0196\*                   MltB; lytic murein transglycosylase                  473   47/47    12    \+             IM (9.97)   \+
  MCR_0439                    Pbp1A; penicillin-binding protein 1A                  786   47/47    5                    IM (9.82)   \+
  MCR_0560                            hypothetical protein                          355   44/47    5                     IM (10)    −
  MCR_0681                       putative lytic transglycosylase                    303   45/47    7                    ? (5.02)    \+
  MCR_0686\*            peptide methionine sulfoxide reductase MsrA/MsrB            558   47/47    3     \+   \+   \+   CP (9.26)   \+
  MCR_0691                            hypothetical protein                          105   46/47    4     \+   \+         ? (2.5)    \+
  MCR_0692                            hypothetical protein                          503   45/47    7     \+   \+         ? (2.5)    \+
  MCR_0739                     hemoglobin utilization protein MhuA                  954   46/47    15    \+   \+   \+    OM (10)    \+
  MCR_0918                             M16-like peptidase                           470   46/47    5     \+   \+   \+     ? (2)     \+
  MCR_0996\*                          hypothetical protein                          146   47/47    3          \+        PP (9.84)   \+
  MCR_1003\*                           LysM domain protein                          819   47/47    9     \+             OM (9.49)   \+
  MCR_1010\*                DacC; D-alanyl-D-alanine carboxypeptidase               386   47/47    48                   PP (9.76)   −
  MCR_1228                     D15 surface antigen family protein                   907   47/47    4     \+             OM (9.52)   −
  MCR_1303\*    OppA; oligopeptide ABC transport system substrate binding protein   679   47/47    6     \+   \+   \+   ? (5.02)    \+
  MCR_1357                     Cyt1; cytochrome c1 family protein                   241   47/47    22                    ? (2.5)    −
  MCR_1416\*                       cytochrome c class II Msp22                      152   47/47    2                    PP (9.44)   \+
  MCR_1690                extracellular solute-binding protein family 3             262   44/47    6          \+         PP (10)    \+
  MCR_1742                           outer membrane protein                         111   46/47    24                    ? (2.5)    \+
  MCR_1761                          OlpA; OPA-like protein A                        235   47/47    7     \+              OM (10)    −

aa, amino acids; GD, gene distribution; 1, Proteins detected in the whole membrane preparation; 2, Proteins detected in outer membrane vesicles (iron-rich conditions); 3, Proteins detected in outer membrane vesicles (iron-depleted conditions); 4, Bioinformatic analysis, predicted localization using PSORTb3.0.3 (score), OM  =  outer membrane, PP  =  periplasmic, IM  =  inner membrane, CP  =  cytoplasmic, ?  =  unknown; 5, Peptide ELISA (+; at least one peptide with an average ELISA unit ≥100); \*selected for *in vivo* studies.

Three candidate vaccine antigens demonstrated protection *in vivo* {#s3c}
------------------------------------------------------------------

Of the 23 candidates selected by the ANTIGENome technology, we evaluated 8 well conserved (see [Table 5](#pone-0064422-t005){ref-type="table"}) and readily recombinant expressed antigens that had shown some promise in a preliminary mouse study in more detail for their potential to elicit protective immune response *in vivo* ([Figure 1](#pone-0064422-g001){ref-type="fig"}). The rate of *M. catarrhalis* clearance from mouse lungs in response to immunization with recombinant antigens was assessed using a mouse pulmonary clearance model ([Figure 2](#pone-0064422-g002){ref-type="fig"}). Mice were immunized intranasally 3 times at 3 week intervals and challenged intranasally with 40 µL of approximately 5×10^6^ live *M. catarrhalis* RH4 (actual CFU varied between 3.8×10^6^ to 5.9×10^6^) 3 weeks after the last boost. Bacterial CFU were determined in lungs 6 hours post infection and systemic antibody titers after vaccination of mice were determined by ELISA ([Figure 2](#pone-0064422-g002){ref-type="fig"}).

![Structural features of 8 potential *M. catarrhalis* vaccine candidates.\
MCR_0076, TonB-dependent receptor; MCR_0196, MltB; lytic murein transglycosylase; MCR_0686, peptide methionine sulfoxide reductase MsrA/MsrB; MCR_0996, hypothetical protein; MCR_1003, LysM domain protein; MCR_1010, D-alanyl-D-alanine carboxypeptidase; MCR_1303, oligopeptide ABC transport system substrate binding protein; MCR_1416, cytochrome c class II, Msp22. SP, signal peptide; LP, signal peptide for lipidation; Plug, an independent folding subunit blocking the pore until the channel is bound by a ligand; PGBD1, peptidoglycan binding-like; MsrA, methionine sulfoxide reductase A; SelR, seleno protein R; LysM, lysine motif; SBP bac 5, bacterial extracellular solute-binding protein family 5. Light grey bars represent the recombinant protein (fragments). Thin black bars delineate epitope containing regions covered by clones selected by the ANTIGENome technology with human IgGs.](pone.0064422.g001){#pone-0064422-g001}

![Pulmonary clearance of *M. catarrhalis* RH4 after intranasal challenge following intranasal immunization with 8 selected antigens.\
Pulmonary clearance 6 hours after intranasal challenge with ∼5×10^6^ CFU *M. catarrhalis*, in mice immunized with purified, IC31^®^ adjuvanted recombinant proteins, IC31^®^ adjuvant without proteins in PBS, or PBS without adjuvant. The mean values of the combined, normalized results from 2 to 6 independent experiments are shown. Error bars represent the standard error of the mean. (A) Bacterial CFU recovered from all experiments; (B) bacterial CFU recovered from experiments after exclusion of sterile lung cultures. Black bars: negative and positive controls (data from 6 experiments), grey bars: data from 2 to 3 independent experiments in which different antigens were tested. (C) ELISA measuring IgG levels to the respective recombinant proteins in serum from mice immunized intranasally with purified recombinant proteins as noted below the x-axis. For the controls (IC31^®^ alone or PBS), IgG levels were determined using a mix of all recombinant proteins. Endpoint titers were expressed as the last dilution that gave an absorbance of at least 0.1 at 405 nm. Median values with the interquartile range from 2 to 6 independent experiments using 10 sera (10 mice per group) per experiment are shown. \*\*, statistically highly significant (P\<0.01), \*, statistically significant (P\<0.05).](pone.0064422.g002){#pone-0064422-g002}

10.1371/journal.pone.0064422.t005

###### Properties of aligned polypeptide sequences for 8 potential *M. catarrhalis* vaccine candidates.
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  ORF         aa Start-Stop   Length   No. of non-synonymous/deleted aa   No. of isolates
  ---------- --------------- -------- ---------------------------------- -----------------
  MCR_0076       21--160       140                    10                        62
  MCR_0196       36--485       450                    32                        63
  MCR_0686       28--558       531                    28                        64
  MCR_0996       27--148       122                    21                        64
  MCR_1003       30--375       346                   7\#                        64
  MCR_1010       27--386       360                    21                        64
  MCR_1303       24--679       656                    31                        64
  MCR_1416       21--152       132                    6                         64

Sequences were aligned using the Bionumerics algorithm (Bionumerics v 6.0 software, Applied Maths) and default settings. Length, length in translated amino acids. \#, a single insertion event of 12 amino acids was also observed in a single isolate for this vaccine candidate.

Groups of mice immunized with recombinant proteins MCR_1416, MCR_1303, MCR_0076-1, MCR_1010, MCR_0196, MCR_1003-1, MCR_0996 and MCR_0686 expressed in *E. coli* showed a greater or comparable clearance of bacteria from lungs compared to the positive control protein OmpCD ([Figure 2A, B](#pone-0064422-g002){ref-type="fig"}). The effect was statistically significant for MCR_1416 with one log reduction in bacterial recovery compared to mice immunized with adjuvant alone (IC31^®^) (p\<0.01) ([Figure 2A](#pone-0064422-g002){ref-type="fig"}). Further, there was also a significant reduction in bacterial load for MCR_1303 (p\<0.05) and MCR_0076-1 (p\<0.05) compared to IC31^®^ alone, when sterile lung cultures were removed from the analysis ([Figure 2B](#pone-0064422-g002){ref-type="fig"}). The exclusion of sterile cultures was considered reasonable, based on the observation that negative (sterile) lung cultures appeared randomly between 0 to 3 in the 6 PBS groups, the number of sterile lung cultures in the immunized mice occurred with the same frequency as in the PBS groups (between 0 and 4). Therefore, the sterile lung cultures were more likely to represent a technical artifact (infection failure), rather than elimination of bacteria. While significant protection was observed for MCR_1416, MCR_1303 and MCR_0076-1, protection was lower for the other candidates despite strong antibody responses as measured by IgG ELISA ([Figure 2C](#pone-0064422-g002){ref-type="fig"}). In contrast, the IgG response was very low for MCR_0076-1 and MCR_1010, while the level of protection was higher than for the positive control protein OmpCD. This observation indicated that factors other than antibody responses may contribute to protection against *M. catarrhalis*.

Systemic human antibody responses against the selected antigens are not induced upon infection {#s3d}
----------------------------------------------------------------------------------------------

In order to evaluate the human immune response for the 8 selected recombinant antigens upon natural infection, additional serological studies were performed with ELISA and Luminex xMAP^®^ technology, using a collection of 164 individual sera from children with otitis media collected during the acute and convalescent disease phase. Sera from healthy individuals were tested in parallel in order to compare antigen specific responses between healthy adults and children with otitis media. We detected antibodies against all eight antigens in the 20 paired acute/convalescent serum samples from children with otitis media, however IgG end titers were relatively low (\<2000) and no significant antigen specific seroconversion (defined as ≥2 fold increase in the convalescent IgG titer) was detected in any of the donors (data not shown). We also examined the median antibody titers between healthy donors and otitis media patients, however no statistically significant difference was seen (data not shown). Moreover, we detected a decrease in median systemic IgG titers against the antigen MCR_1303 in convalescent sera compared to acute sera (data not shown). These results are in agreement with the peptide ELISA data, as no increase in antibody titer was detected for these antigens in sera from otitis media patients during an OM episode when the paired serum samples were collected.

MCR_1416 exhibits heme-dependent peroxidase activity {#s3e}
----------------------------------------------------

The recombinant antigen showing the highest protection in the pulmonary clearance model was further studied for its biological function. MCR_1416 has previously been identified as *Moraxella* surface protein 22 (Msp22) [@pone.0064422-Ruckdeschel1] and shows homology to cytochrome *c*, it containing one CXXCH motif (residues 142 to 146). C-type cytochromes are characterized by covalent attachment of heme to the protein via two thioether bonds formed between the heme vinyl groups and the cysteine sulfurs in a CXXCH peptide motif [@pone.0064422-ThonyMeyer1]. Since Msp22 also contains this motif, we set out to determine whether it binds heme and exhibits heme-dependent peroxidase activity. Heme staining was performed according to the method of Feissner *et al.* [@pone.0064422-Feissner1] using luminol as substrate for the heme-dependent peroxidase activity.

In order to try to ensure that native lipidated Msp22 protein was recovered possessing its correct native conformational folding, Msp22 with its native signal sequence and a C-terminal His-tag was expressed in *M. catarrhalis* (i.e. its native host), using the complementation vector pEMCJH04-KAN. We complemented the wild type strain with the plasmid expressed Msp22 in order to increase the yield of purification from *M. catarrhalis*. Subsequently, Msp22 was obtained from the soluble fraction and purified on an IMAC column. Western blot analyses of the column eluate (using extracts from *M. catarrhalis* with or without pEMCJH04-KAN-Msp22-HIS) and immune sera against recombinant MCR_1416 and anti-penta-His antibody revealed successful purification of His-tagged Msp22 ([Figure 3](#pone-0064422-g003){ref-type="fig"}). These experiments also showed that the Msp22 protein as produced by wild type *M. catarrhalis* is recognized by antibodies induced in mice by the recombinant *E. coli* protein.

![Detection of recombinant MCR_1416 (Msp22) expressed and purified from *M. catarrhalis*.\
Equal volumes of eluates obtained from IMAC columns from extracts of *M. catarrhalis* complemented with His-tagged MCR_1416 (eluate A) or wild type strain (not complemented, negative control) were separated by SDS-PAGE and immunoblotted using immune serum against recombinant Msp22 (left panel) and antibody against the His-tag (right panel).](pone.0064422.g003){#pone-0064422-g003}

For heme detection experiments, samples were prepared using a non-reducing sample buffer and were not heated prior to SDS-PAGE, which was performed under denaturing conditions. Bacterial lysates of the wild type, the *msp22* gene deletion mutant and the complemented strains all served as additional heme controls. Positive signals were obtained for hemoglobin, purified Msp22 and the cell lysates expressing Msp22, indicating the presence of heme-dependent peroxidase activity. No signal was detected for the negative control protein BSA ([Figure 4](#pone-0064422-g004){ref-type="fig"}). The absence of the respective protein band at 17 kDa in the *msp22* gene deletion mutant, the presence of a strong signal in the complemented strain, and a weak signal in the wild type strain suggested that the 17 kDa hemoprotein was indeed Msp22.

![Msp22 shows heme-dependent peroxidase activity.\
The specificity of the heme stain for Msp22 is demonstrated by staining of lysates from the wild type, and gene deletion mutant strains as well as the BBH18 strain transformed with pEMCJH04-KAN-Msp22. Hemoglobin (positive control), BSA (negative control). wt, wild type *M. catarrhalis* BBH18; wt c\*, wild type *M. catarrhalis* BBH18 transformed with pEMCJH04-KAN-Msp22; msp22Δ, msp22 gene deletion mutant; msp22Δ c\* msp22 gene deletion mutant transformed with pEMCJH04-KAN-Msp22. The position of Msp22 is marked with an arrow.](pone.0064422.g004){#pone-0064422-g004}

Discussion {#s4}
==========

Over the last three decades, *M. catarrhalis* has become recognized as an important pathogen of the human respiratory tract [@pone.0064422-Murphy5], [@pone.0064422-Johnson1], [@pone.0064422-Malmvall1], [@pone.0064422-Murphy6], [@pone.0064422-Nicotra1], [@pone.0064422-Shann1], [@pone.0064422-Waters1]. However, even though *M. catarrhalis* is the third most frequent bacterial pathogen to be associated with otitis media and is a major cause of exacerbations of COPD in adults, none of the currently available bacterial vaccines developed to prevent these diseases include *M. catarrhalis* antigens [@pone.0064422-Murphy3]. Therefore, the aim of this study was to comprehensively identify potential vaccine targets of *M. catarrhalis* by applying the ANTIGENome technology that had previously been developed by Intercell AG (Vienna, Austria), and which had been previously successfully used for vaccine discovery for several other bacterial pathogens [@pone.0064422-Fritzer1], [@pone.0064422-Meinke1], [@pone.0064422-Meinke3]. Genomic libraries displaying multiple epitopes of all potential antigens of isolate BBH18 were screened using human IgG pools from patients as well as healthy individuals, anticipating identification of antigens expressed during infection *in vivo*. The most frequently selected antigens in the screens were Hag/MID and UspA1, which are vaccine candidate antigens previously identified in other studies. Hag/MID has been described as an adhesin, a hemagglutinin, and a stimulator of B cells [@pone.0064422-Balder1], [@pone.0064422-Pearson1], whilst UspA1 functions as an adhesin and a transporter [@pone.0064422-Aebi3], [@pone.0064422-Hoiczyk1]. Further, immunization with UspA1 has been shown to induce bactericidal antibodies in mice and humans [@pone.0064422-Chen2]. In fact, the detection of these well-known candidate antigens shows the value of the ANTIGENome technology in identifying potential vaccine candidates, also including potentially novel vaccine candidates. Indeed, using this technology, allowed the identification of 214 antigenic *M. catarrhalis* proteins, with 23 of these candidates being further evaluated in a murine *M. catarrhalis* pulmonary clearance model.

The fact that *M. catarrhalis* is a strictly human pathogen, which does not induce active infection in animals, means that there is currently no clinically relevant model for *M. catarrhalis* vaccination studies available, especially for studies that adequately mimic otitis media infection in humans. For this reason, the mouse pulmonary clearance model is the most frequently used animal model to test the ability of antigens to generate a protective immune response against *M. catarrhalis* [@pone.0064422-Sabirov1]. However, it is known that mice do not develop pneumonia and are able to clear the *M. catarrhalis* bacteria relatively quickly in this model (within 6--24 hours), and in this study, *M. catarrhalis* clearance occurred within 24 hrs post-infection. It is precisely for this reason that the clearance of *M. catarrhalis* from the respiratory tract was measured at 6 to 9 hrs post-infection when using this animal model, rather than measuring total bacterial clearance at 24 hrs (by which time non-vaccination related factors could have influenced the clearance of the *M. catarrhalis* bacteria) [@pone.0064422-Unhanand1]. Based on our preliminary studies with heat killed bacteria and the OmpCD antigen, the optimal end point for *M. catarrhalis* strain RH4 in our model was 6 hrs post-infection. This model was found to be reproducible, as we detected similar clearance rates for the tested antigens in up to 6 independent experiments. Nevertheless, it should be noted that the clearance rate of bacteria from the lungs of vaccinated mice (a measure of the efficacy of vaccination) was based on an actual increase in clearance rate compared to the normal clearance rate observed in unvaccinated control mice. In our study, this meant that the maximum clearance rate we observed using this model lay in the range of 0.5 to 1.0 log10 when compared to negative controls. However, our results are in agreement with similar studies that have previously been performed using putative *M. catarrhalis* vaccine antigen candidates [@pone.0064422-Becker1], [@pone.0064422-Liu1], [@pone.0064422-Ruckdeschel2].

Using our comprehensive screening technology, we eventually selected 8 out of the 23 proteins that possessed the potential to become vaccine candidates for testing in a mouse pulmonary clearance model. Three of these protein antigens showed beneficial effects on bacterial clearance from mouse lungs after mucosal immunization: 1) MCR_1416 (Msp22), a candidate also previously identified by Ruckdeschel and colleagues [@pone.0064422-Ruckdeschel1], [@pone.0064422-Ruckdeschel2]; 2) MCR_1303 (OppA), an oligopeptide permease A [@pone.0064422-Yang1] and 3) MCR_0076, the "plug" domain of a TonB-dependent receptor. The fact that similar results and clearance rates were obtained independently by other investigators for Msp22 [@pone.0064422-Ruckdeschel2] and OppA [@pone.0064422-Yang1] using different experimental set-ups, indicates that these proteins are indeed promising vaccine candidates. MCR_0076, the plug domain of TonB-dependent receptor, is situated within the beta-barrel structure and appears to be more conserved than the barrel. This plug domain is an independent folding subunit blocking the pore until the channel is bound by a ligand and causes the structural and functional differences between these transporters and porins [@pone.0064422-Ferguson1], [@pone.0064422-Locher1], [@pone.0064422-Ferguson2]. TonB-dependent receptors have previously been reported to be potential vaccine antigens and important virulence factors [@pone.0064422-Afonina1], [@pone.0064422-Murphy7], [@pone.0064422-Tauseef1] and should thus be taken into consideration and analyzed in more detail for *M. catarrhalis*. The *oppA* gene (MCR_1303) encodes an oligopeptide permease that belongs to the ABC transport system. These types of transporters have been shown to play a role in virulence, to be immunogenic and to be potential vaccine candidates [@pone.0064422-Garmory1]. The Msp22 antigen (MCR_1416) induced the most significant *in vivo* protection and was analyzed *in vitro* in more detail in order to explore its function. Due to its homology to cytochrome c and the presence of a CXXCH motif, known to be involved in heme binding, we tested whether this antigen was indeed a heme binding protein. Our heme staining experiment ([Figure 4](#pone-0064422-g004){ref-type="fig"}) demonstrated that heme had indeed been covalently attached to the highly soluble Msp22 protein, indicating that Msp22 may exert its function via heme binding.

The heme group of type *c* cytochromes accepts electrons from the bc1 complex and transfers them to the cytochrome oxidase complex. Among other functions, cytochrome *c* has heme-dependent peroxidase activity and plays a role in initiation of apoptosis in more complex organisms [@pone.0064422-Chauhan1], [@pone.0064422-Liu2], [@pone.0064422-Huttemann1], [@pone.0064422-Caroppi1]. Based on its homology to cytochrome c and its heme binding, Msp22 may also function in the electron transfer via its heme-dependent peroxidase activity. Besides its important role for cytochrome function, heme is also the most abundant source of iron in the human body [@pone.0064422-Otto1]. Not surprisingly, due to very limited free iron availability in the human host, many pathogens have evolved mechanisms to utilize heme containing proteins as iron sources. Recently, two *M. catarrhalis* proteins have been shown to acquire iron from hemin and heme complexes [@pone.0064422-Furano1], [@pone.0064422-Furano2]. Therefore, Msp22 could also be involved in iron acquisition from heme and heme-containing compounds. Interestingly, it was recently suggested that Msp22 has a potential role in divalent ion transport [@pone.0064422-Yang1]. An investigation into the mechanism of heme binding and the contribution of the CXXCH motif was recently performed for two putative cytochrome *c* peroxidases of *Campylobacter jejuni* [@pone.0064422-Feissner1], [@pone.0064422-BinghamRamos1]. While these proteins exhibited heme binding, site-directed mutations within the CXXCH motif resulted in unstable proteins excluding them from further analysis [@pone.0064422-BinghamRamos1]. Whether this holds true also for *M. catarrhalis* Msp22 remains to be elucidated.

As targets for protective immune responses need to be accessible on the bacterial surface and knowing that Msp22 has been annotated as a putative surface protein, we attempted to confirm the cell surface location of Msp22. However, using flow cytometry of both wild type and Msp22 overexpressing strains and polyclonal anti-Msp22 mouse sera, we could not detect this protein on the bacterial surface. This suggests that the protein is not surface exposed under the *in vitro* growth conditions tested in these studies. In order to elicit a protective immune response, one may speculate that Msp22 may become transiently exposed to the host\'s immune system during infection. Unlike Msp22, OppA is accessible on the bacterial surface *in vitro* [@pone.0064422-Yang1] as confirmed by our studies (data not shown), and antibody mediated neutralization of bacteria is therefore likely to be an important protective immune mechanism complementing native immune defenses against this antigen.

Interestingly, in agreement with the data obtained by other researchers in this field [@pone.0064422-Yang1], we could not detect significant differences in the antibody titers against the 8 tested antigens in; 1) sera from children with otitis media in the acute compared to the convalescent disease phase, or 2) in sera from children compared to sera from healthy individuals. The natural systemic IgG response observed in humans has therefore not provided any further validation of our selected eight antigens, but the selection as a vaccine candidate was rather based on the pulmonary clearance model. Furthermore, although UspA1, UspA2 and Hag/MID antigen specific antibodies were frequently found in both children and healthy individuals [@pone.0064422-StutzmannMeier1], [@pone.0064422-Verhaegh1], there is no clear evidence that natural immune responses raised against other putative vaccine candidates contribute to protection. The question whether naturally induced antibodies against any *M. catarrhalis* antigens play a role in protection against otitis media has been previously raised [@pone.0064422-Yang1], and our observations confirm that further investigations into the immune mechanisms operating during *M. catarrhalis* infection induced by this pathogen will be required. In addition, naturally occurring antibodies may exhibit different epitope specificity and avidity, compared to vaccine induced antibodies. But more importantly, systemic IgG levels do not adequately reflect mucosal immune responses. Thus, if mucosal immunity is more critical for protection against *M. catarrhalis*, serological studies based on serum samples collected from otitis media patients may be of limited value. Such a discrepancy between mucosal and systemic serological immune responses was previously detected in otitis media patients against *M. catarrhalis* outer membrane antigens [@pone.0064422-Faden1]. In addition, the role of T cells for protection and B cell activity stimulation remains to be elucidated. Most recent studies suggested that *M. catarrhalis* is able to modulate mucosal epithelial responses and B cell adaptive immunity in such a way as to hinder the generation of antibodies with a correct function and epitope specificity [@pone.0064422-Schaar1], [@pone.0064422-PerezVidakovics1]. If this indeed turns out to be the case, vaccination with *M. catarrhalis* would be an extremely valuable approach in preventing infection by this pathogen. In terms of antigen validation, the detection of a natural immune response against the selected antigens indicated that they were expressed *in vivo* upon infection of the human host.

In conclusion, comprehensive screening using the ANTIGENome technology has led to the identification of 214 antigenic proteins, with 3 of these being shown to provide protection against *M. catarrhalis* colonization in a mouse pulmonary model. The results confirm that further evaluation of these proteins as vaccine candidates in additional functional studies and in clinically relevant *Moraxella* otitis media models is warranted.
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